Clinical Trial Update: A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [EARLY_Phase 1]

View source ↗

Summary

A Phase I/IIa open-label trial evaluating IMV101 as a single agent for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• IMV101

Snippet

Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd | Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | EARLY_Phase 1 | Status: RECRUITING